A biotech and life sciences company focused on developing clinical therapeutic programs, particularly in dermatology. The company is advancing SKNJCT-003, a treatment candidate in Phase 2 development for basal cell carcinoma, and has established strategic collaborations to expand its pipeline in rare skin conditions.